Zymeworks Inc

Zymeworks Inc. is a biopharmaceutical company. It engages in the discovery, development, and commercialization of multifunctional biotherapeutics, initially focused on the treatment of cancer. The company is headquartered in Middletown, DE.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zymeworks reports turnaround year with strong financials and R&D progress

Zymeworks delivered a strong financial performance in 2022, driven by revenue growth and cost management efforts.
The company faces challenges in managing increased expenses and addressing analyst inquiries on data disclosure and product development.
Despite challenges, Zymeworks remains well-positioned with ample cash resources and a robust R&D pipeline for future growth.
Opportunities lie in expanding partnerships, leveraging positive trial data, and showcasing innovation at upcoming industry events.

Zymeworks Inc reports revenue growth and strategic R&D advancements

Zymeworks Inc's Q1 2023 performance reflects positive financial trends and advancements in their R&D programs and partnerships.
While challenges exist with the Jazz agreement and future clinical trials, the company is strategically positioned for growth.
Opportunities in global collaborations, capital allocation, and innovative therapies position Zymeworks for future success and market expansion.

Zymeworks reports improved financials, advances global clinical expertise

Zymeworks Inc's Q2 2023 performance reflects a mixed financial picture with revenue growth but increased expenses, while maintaining a healthy cash position.
The company's strengths lie in advancing its product pipeline, leveraging partnerships for efficient development, and establishing global clinical expertise.
Challenges include timeline uncertainties, competitive landscape considerations, and operational complexities in clinical trial development.
Opportunities abound in therapeutic advancements, strategic partnerships, and long-term financial sustainability through disciplined management.

Zymeworks Inc reports improved financials and optimistic drug outlook

Zymeworks Inc's Q3 2023 performance reflects improved financials driven by revenue growth from collaborations, cost management strategies, and operational streamlining.
The company's strengths lie in new IND candidates, positive outlook on key drug opportunities, and confidence in study designs and treatment efficacy.
Challenges include managing expense trajectories, balancing cost structures, and optimizing cash resources for sustained operations and growth.
Opportunities abound in continued collaboration benefits, pipeline expansion in targeted cancer therapies, and advancements in preclinical assets for future clinical studies.

Zymeworks accelerates pipeline development with positive clinical results and partnerships

Zymeworks demonstrated positive performance in clinical trials and financial management in Q4 2023.
Strengths lie in pipeline progress, resource independence, and potential milestone payments.
Challenges include financial losses, competition, and the need for strategic partnerships.
Opportunities exist in partnerships, milestone payments, and upcoming data readouts for market impact.

Zymeworks Inc reports Q1 loss, focuses on T cell enhancement

Zymeworks Inc is strategically positioned to advance its clinical development programs and strengthen its presence in key locations for upcoming trials. The company is committed to executing its plan efficiently, focusing on enhancing T cell responses and exploring opportunities for sustainable growth.

Zymeworks reports Q2 losses, advances oncology pipeline with FDA clearances

Zymeworks' Q2 2024 performance reflects a mix of financial challenges and strategic advancements in drug development and regulatory milestones.
The company's strengths lie in its pipeline progress, strategic decision-making, and focus on growth through key appointments and partnerships.
While facing challenges in financial metrics and product timelines, Zymeworks has opportunities to leverage its resources for future growth and innovation.

Zymeworks reports revenue decline but showcases strength in innovation and financial strategy

Zymeworks reported a decline in revenue and a net loss for Q3 2024, reflecting ongoing financial challenges.
Despite this, the company showcased strengths in preclinical data, share repurchase program, and commitment to innovation.
Navigating market conditions and managing expenses will be crucial, but Zymeworks has opportunities in new therapeutic areas and strategic initiatives.
Investors should monitor the company's progress, especially with the upcoming R&D Day and potential advancements in its pipeline.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.

The Zymeworks story over the last two years was one of transformation and execution. Ziihera (zanidatamab) was approved in November for the treatment of second line biliary tract cancer and Zymeworks should start generating royalties on net sales this quarter. The phase 3 results for Ziihera in first-line GEA patients are now expected in Q2 2025, and represent the next critical step for Zymeworks and its partner Jazz.

Zymeworks: Prime Time For Ziihera, Early-Stage Pipeline Progressing Ahead Of Schedule

VANCOUVER, British Columbia, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences:

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced, with Jazz Pharmaceuticals, that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Ziihera® (zanidatamab-hrii) 50mg/mL for injection for intravenous use for the treatment of adults with previously-treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test.1 Ziihera was approved under accelerated approval based on a 52% objective response rate (ORR) and a median duration of response (DOR) of 14.9 months as determined by independent central review (ICR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.1 The approval of Ziihera, which previously received Breakthrough Therapy Designation from the FDA for this indication, is an important advance and offers the first and only dual HER2-targeted bispecific antibody and chemotherapy-free treatment for patients living with BTC.

FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

Global Phase 1 clinical trial will evaluate the safety and tolerability of ZW191 in treatment of advanced cancers including ovarian, endometrial, and non-small cell lung cancers Global Phase 1 clinical trial will evaluate the safety and tolerability of ZW191 in treatment of advanced cancers including ovarian, endometrial, and non-small cell lung cancers

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors

The PDUFA date for potential approval of Zanidatamab for the treatment of patients with 2nd-line biliary tract cancer set for November 29th of 2024. Progression-free survival data from the phase 3 HERIZON-GEA-01 study using Zanidatamab + chemotherapy plus or minus tislelizumab for treatment of patients with 1st-line GEA is expected in Q2 of 2025. Zanidatamab is being developed in collaboration with two big pharmaceutical companies, which are Jazz Pharmaceuticals and BeiGene.

Zymeworks: Turning The Tide With 2 Key Milestones For Zanidatamab

Zymeworks Inc. (NASDAQ:ZYME ) Q3 2024 Earnings Conference Call October 31, 2024 4:30 PM ET Company Participants Shrinal Inamdar - Director, Investor Relations Leone Patterson - Executive Vice President, Chief Business and Financial Officer Paul Moore - Chief Scientific Officer Kenneth Galbraith - Chair and Chief executive Officer Conference Call Participants Stephen Willey - Stifel Ashiq Mubarack - Citi Brian Cheng - JPMorgan Jon Miller - Evercore ISI Derek Achila - Wells Fargo Operator Hello. Thank you for standing by.

Zymeworks Inc. (ZYME) Q3 2024 Earnings Call Transcript

Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.41 per share a year ago.

Zymeworks Inc. (ZYME) Reports Q3 Loss, Lags Revenue Estimates

VANCOUVER, British Columbia, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced new preclinical data for Zymeworks' antibody-drug conjugate (ADC) candidates ZW220 and ZW251 in presentations at the European Organisation for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research (EORTC-NCI-AACR) Conference taking place in Barcelona on October 23-25, 2024.

Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

VANCOUVER, British Columbia, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the first patient has been dosed in the first-in-human Phase 1 trial (NCT06523803) to evaluate the safety and tolerability of the investigational therapy ZW171 in the treatment of advanced or metastatic ovarian cancer, NSCLC, and other MSLN-expressing cancers.

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers

VANCOUVER, British Columbia, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will report its third quarter 2024 financial results after market close on October 31, 2024. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on October 31, 2024 at 4:30 pm Eastern Time (ET).

Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024

ZYME's zanidatamab is under regulatory review for the treatment of second-line HER2-positive biliary tract cancer, with potential US approval in November 2024. Subsequent approval in the same indication could follow in the EU as early as Q2 '25, and in China in H2 '25. A readout from the HERIZON-GEA-01 study of zanidatamab in gastroesophageal adenocarcinoma in Q2 '25 represents a major clinical catalyst for ZYME.

Zymeworks Approaching A Moment Of Truth With Zanidatamab

Presentations to highlight progress in development of IND candidates ZW220 and ZW251 based on Zymeworks' proprietary antibody-drug conjugate development platforms Presentations to highlight progress in development of IND candidates ZW220 and ZW251 based on Zymeworks' proprietary antibody-drug conjugate development platforms

Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

VANCOUVER, British Columbia, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today reported, as required by the Nasdaq Stock Market Rule 5635(c) (the “Nasdaq Rule”), an equity inducement award to Ms. Leone Patterson, Zymeworks' Executive Vice President and Chief Business and Financial Officer.

Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)

Zymeworks Inc. (NASDAQ:ZYME ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Shrinal Inamdar - Director, Investor Relations Bijal Desai - Vice President-Finance & Strategy Paul Moore - Chief Scientific Officer Ken Galbraith - Chair & Chief Executive Officer Pranshul Chauhan - Associate Medical Director Conference Call Participants Stephen Willey - Stifel Jon Miller - Evercore Robert Burns - H.C. Wainwright Operator Thank you for standing by.

Zymeworks Inc. (ZYME) Q2 2024 Earnings Call Transcript

Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.76 per share a year ago.

Zymeworks Inc. (ZYME) Reports Q2 Loss, Misses Revenue Estimates

Zymeworks intends to commence the Share Repurchase Program with $30.0 million in initial repurchases anticipated to begin promptly and continue during the second half of 2024 Zymeworks intends to commence the Share Repurchase Program with $30.0 million in initial repurchases anticipated to begin promptly and continue during the second half of 2024

Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock

VANCOUVER, British Columbia, July 25, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appointment of Leone Patterson as Executive Vice President, and Chief Business and Financial Officer, effective September 1, 2024.

Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer

VANCOUVER, British Columbia, July 22, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for ZW191, the Company's novel folate receptor-⍺ (FR⍺) targeted topoisomerase I inhibitor (TOPO1i) antibody-drug conjugate (ADC).

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate

VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will report its second quarter 2024 financial results after market close on August 1, 2024. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on August 1, 2024 at 4:30 pm Eastern Time (ET).

Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024

VANCOUVER, British Columbia, June 17, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for ZW171, a novel 2+1 T-cell targeting bispecific antibody for mesothelin (MSLN)-expressing cancers.

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers

VANCOUVER, British Columbia, June 10, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China has accepted the BLA for zanidatamab for second-line treatment of HER2-positive BTC. Under the terms of Zymeworks' Asia Pacific license and collaboration agreement with BeiGene for the development and commercialization of zanidatamab, Zymeworks is entitled to receive an $8 million milestone payment. Zymeworks also remains eligible to receive up to $164 million based on additional milestones plus royalties on product sales in the Asia Pacific region.

Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer

NEW YORK, NY / ACCESSWIRE / May 31, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc. ("Zymeworks") (NASDAQ:ZYME) concerning possible violations of federal securities laws. Zymeworks disclosed, on April 1, 2024, that it had removed Christopher Astle ("Astle") from the positions of Senior Vice President ("SVP") and Chief Financial Officer ("CFO"), effective immediately.

Zymeworks Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- ZYME

NEW YORK, NY / ACCESSWIRE / May 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc. ("Zymeworks") (NASDAQ:ZYME) concerning possible violations of federal securities laws. Zymeworks disclosed, on April 1, 2024, that it had removed Christopher Astle ("Astle") from the positions of Senior Vice President ("SVP") and Chief Financial Officer ("CFO"), effective immediately.

Levi & Korsinsky Reminds Zymeworks Investors of the Ongoing Investigation into Potential Violations of Securities Laws - ZYME

NEW YORK, NY / ACCESSWIRE / May 17, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc. ("Zymeworks") (NASDAQ:ZYME) concerning possible violations of federal securities laws. Zymeworks disclosed, on April 1, 2024, that it had removed Christopher Astle ("Astle") from the positions of Senior Vice President ("SVP") and Chief Financial Officer ("CFO"), effective immediately.

Lost Money on Zymeworks Inc.(ZYME)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky

NEW YORK--(BUSINESS WIRE)-- #Investigation--The law firm of Kirby McInerney LLP reminds investors that the firm is investigating potential claims against Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME). The firm's ongoing investigation concerns whether Zymeworks and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [Click here to learn more about the investigation] On April 1, 2024, Zymeworks disclosed that it had removed Chris.

News for Zymeworks Inc Stock (ZYME)